BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.326
+0.003 (0.96%)
At close: Jan 31, 2025, 4:00 PM
0.318
-0.008 (-2.45%)
After-hours: Jan 31, 2025, 6:17 PM EST
BioXcel Therapeutics Employees
BioXcel Therapeutics had 74 employees as of December 31, 2023. The number of employees decreased by 109 or -59.56% compared to the previous year.
Employees
74
Change (1Y)
-109
Growth (1Y)
-59.56%
Revenue / Employee
$30,757
Profits / Employee
-$959,405
Market Cap
16.18M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BTAI News
- 2 months ago - BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics to Present at ThinkEquity Conference - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - GlobeNewsWire
- 4 months ago - BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - GlobeNewsWire
- 5 months ago - BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire